netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Gemcitabine found 16 matches

Formulary items 4 matches
Non-formulary items 1 match
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Gemcitabine Malignant disease and immunosuppression - Antimetabolites - 08.01.03
  Cytotoxic Drug Capecitabine Malignant disease and immunosuppression - Antimetabolites - 08.01.03
  Cytotoxic Drug Durvalumab  (Imfinzi®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Paclitaxel - Albumin Bound Formulation  (Abraxane®) Malignant disease and immunosuppression - Taxanes - 08.01.05
 
Non Formulary BNF Category
  Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NHS England SSC1959 - Clinical Commissioning Policy: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages) (08.01.03)
link in drug section NHS England SSC1959 - Clinical Commissioning Policy: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages) (08.01.03)
link in drug section NICE TA116: Gemcitabine for the treatment of metastatic breast cancer (08.01.03)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.02)
link in drug section NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.03)
link in drug section NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (08.01.05)
link in drug section NICE TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (08.01.05)
link in drug section NICE TA966: Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (08.01.05)


 
netFormulary